These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 36060266)
1. A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma. Yan X; Wang N; Dong J; Wang F; Zhang J; Hu X; Zhao H; Gao X; Liu Z; Li Y; Hu S Front Mol Biosci; 2022; 9():966843. PubMed ID: 36060266 [TBL] [Abstract][Full Text] [Related]
2. Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma. Miao Y; Liu J; Liu X; Yuan Q; Li H; Zhang Y; Zhan Y; Feng X Front Genet; 2022; 13():951239. PubMed ID: 36186436 [TBL] [Abstract][Full Text] [Related]
3. Prognosis and immune response of a cuproptosis-related lncRNA signature in low grade glioma. Xu Y; Wang C; Li S; Zhou H; Feng Y Front Genet; 2022; 13():975419. PubMed ID: 36338998 [TBL] [Abstract][Full Text] [Related]
4. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma. Wen J; Zhao W; Shu X Front Oncol; 2022; 12():1087762. PubMed ID: 36776374 [TBL] [Abstract][Full Text] [Related]
5. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related]
6. A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments. Chen D; Xu Y; Gao X; Zhu X; Liu X; Yan D Front Pharmacol; 2023; 14():1158723. PubMed ID: 37101543 [No Abstract] [Full Text] [Related]
7. Comprehensive analysis of the prognostic signature and tumor microenvironment infiltration characteristics of cuproptosis-related lncRNAs for patients with colon adenocarcinoma. Cui G; Liu J; Wang C; Gu R; Wang M; Sun Z; Wei F Front Oncol; 2022; 12():1007918. PubMed ID: 36212459 [TBL] [Abstract][Full Text] [Related]
8. Novel Cuproptosis-Related Gene Signature for Precise Identification of High-Risk Populations in Low-Grade Gliomas. Chen P; Han H; Wang X; Wang B; Wang Z Mediators Inflamm; 2023; 2023():6232620. PubMed ID: 36814682 [TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
10. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma. Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C Front Genet; 2023; 14():1124439. PubMed ID: 36936439 [No Abstract] [Full Text] [Related]
11. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients. He Y; Ye Y; Tian W; Qiu H Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662 [No Abstract] [Full Text] [Related]
12. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Zhang M; Wang X; Chen X; Zhang Q; Hong J Front Genet; 2020; 11():363. PubMed ID: 32351547 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer. Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y Front Genet; 2022; 13():984743. PubMed ID: 36467996 [No Abstract] [Full Text] [Related]
14. A cuproptosis-based prognostic model for predicting survival in low-grade glioma. Zhao Z; Ma Y; Liu Y; Chen Z; Zheng J Aging (Albany NY); 2024 May; 16(10):8697-8716. PubMed ID: 38738989 [TBL] [Abstract][Full Text] [Related]
15. A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer. Feng A; He L; Chen T; Xu M Front Oncol; 2022; 12():957966. PubMed ID: 36106123 [TBL] [Abstract][Full Text] [Related]
16. Identification of cuproptosis-related lncRNAs for prognosis and immunotherapy in glioma. Wang L; Li Y; Wang Y; Li J; Sun Y; Chen J; Wang Z J Cell Mol Med; 2022 Dec; 26(23):5820-5831. PubMed ID: 36317420 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of a novel cuproptosis-related lncRNA signature associated with prognosis and tumor matrix features to predict immunotherapy in soft tissue carcinoma. Liu B; Pang K; Feng C; Liu Z; Li C; Zhang H; Liu P; Li Z; He S; Tu C Front Genet; 2022; 13():1063057. PubMed ID: 36568384 [No Abstract] [Full Text] [Related]
18. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H Front Genet; 2022; 13():938259. PubMed ID: 35910212 [No Abstract] [Full Text] [Related]
19. A Hypoxia-Related Long Non-Coding RNAs Signature Associated With Prognosis in Lower-Grade Glioma. Feng Q; Qian C; Fan S Front Oncol; 2021; 11():771512. PubMed ID: 34869006 [TBL] [Abstract][Full Text] [Related]
20. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients. Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]